Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.

Also called NCT03851432

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Sihuan Pharmaceutical Holdings Group Ltd. (from the registry)
Registry
  • NCT NCT03851432
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03851432. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-30 (actual); primary completion 2020-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Janagliflozin plus metformin
Intervention (Drug)
Janagliflozin plus metformin
Intervention (Device)
Placebo plus metformin
Lead sponsor
Sihuan Pharmaceutical Holdings Group Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03851432
Content hash
597e4d932ebde22b52626fb20b0cf1ddd70f2ed94dc4937c0aff43015e0d9102